SLC5A2 and diabetes mellitus: Over the past several years, selective inhibitors of SGLT2 (SGLT2i) have been used as effective therapeutic agents to prevent the reabsorption of kidney-filtered glucose, and they are widely used for treatment of hyperglycemia in patients with diabetes mellitus [2].